Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies

(2017) J. J. Stephenson et al.   JOURNAL OF CLINICAL ONCOLOGY

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

(2017) H. S. Pandha et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer

(2017) J. M. Vainshtein et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.

(2017) K. B. Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.

(2017) M. E. Scheulen et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.

(2017) S. E. Minton et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis.

(2017) U. Gürtler et al.   JOURNAL OF CLINICAL ONCOLOGY

Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.

(2017) T. Ohnuma et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

(2017) Sergio Bracarda et al.   JOURNAL OF CLINICAL ONCOLOGY

Automated telephone reminders: Potential to improve adherence to adjuvant hormonal therapy among patients with breast cancer.

(2017) Virginia P. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

(2015) Juan Miguel Mosquera et al.   NEOPLASIA

Cancer Genomics and Inherited Risk

(2014) Zsofia K. Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

(2012) T M Beer et al.   BRITISH JOURNAL OF CANCER

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

(2012) Joel B. Nelson et al.   CANCER

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus

(2012) M. Thadani-Mulero et al.   CANCER RESEARCH

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

(2012) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

(2012) C. M. Chapman et al.   CLINICAL CANCER RESEARCH

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

(2012) W. W. Ma et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

(2012) N. Isambert et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group

(2012) Glenn Liu et al.   Clinical Genitourinary Cancer

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

(2012) A. Frost et al.   Current Oncology

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

(2012) H.J. Meulenbeld et al.   EUROPEAN JOURNAL OF CANCER

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

(2011) K. N. Chi et al.   ANNALS OF ONCOLOGY

A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor

(2011) Nai-Dong Xing et al.   ASIAN JOURNAL OF ANDROLOGY

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

(2011) Wenqing Qi et al.   BIOCHEMICAL PHARMACOLOGY

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

(2011) Italo Beria et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies

(2011) Jacek Jassem et al.   BREAST

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors

(2011) Muhammad Wasif Saif et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

(2011) J. R. Infante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1

(2011) Bing Feng et al.   CANCER LETTERS

Aurora-C kinase supports mitotic progression in the absence of Aurora-B

(2011) Scott D. Slattery et al.   CELL CYCLE

From Plk1 to Plk5

(2011) Guillermo de Cárcer et al.   CELL CYCLE

Overcoming Chemotherapy Resistance in Prostate Cancer

(2011) R. A. Madan et al.   CLINICAL CANCER RESEARCH

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

Ten Years of Docetaxel-Based Therapies in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis of 2244 Patients in 12 Randomized Clinical Trials

(2011) Ary Serpa Neto et al.   Clinical Genitourinary Cancer

Clinically Significant Human Papilloma Virus in Squamous Cell Carcinoma of the Head and Neck in UK Practice

(2011) S. Heath et al.   CLINICAL ONCOLOGY

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

MLN8054, A Small Molecule Inhibitor of Aurora Kinase A, Sensitizes Androgen-Resistant Prostate Cancer to Radiation

(2011) Luigi Moretti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

(2011) Robert L Coleman et al.   LANCET ONCOLOGY

Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer

(2011) M. Marin-Aguilera et al.   MOLECULAR CANCER THERAPEUTICS

The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer

(2011) T. B. Dorff et al.   ONCOLOGIST

Overexpression of Active Aurora-C Kinase Results in Cell Transformation and Tumour Formation

(2011) Jabbar Khan et al.   PLoS One

Enhanced Radiosensitivity of Androgen-Resistant Prostate Cancer: AZD1152-Mediated Aurora Kinase B Inhibition

(2011) Kenneth J Niermann et al.   RADIATION RESEARCH

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032

(2011) David C. Smith et al.   UROLOGY

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy

(2010) Tomasz M. Beer et al.   ANTI-CANCER DRUGS

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

(2010) Gabriel N. Hortobagyi et al.   BREAST CANCER RESEARCH AND TREATMENT

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

(2010) Henri Roché et al.   BREAST CANCER RESEARCH AND TREATMENT

Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial

(2010) Gaetano Facchini et al.   CANCER BIOLOGY & THERAPY

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

(2010) E. Claire Dees et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

(2010) Kyle D. Holen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

(2010) Howard A. Burris et al.   INVESTIGATIONAL NEW DRUGS

Phosphorylation and Activation of Androgen Receptor by Aurora-A

(2010) Shao-Kun Shu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

(2010) Kim N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

(2010) Nicholas D. Adams et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer

(2010) Paul Baas et al.   Journal of Thoracic Oncology

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

(2010) Robert S DiPaola et al.   Journal of Translational Medicine

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-L-Cysteine-Mediated Eg5 Inhibition

(2010) C. Wiltshire et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action

(2010) G. C. Fletcher et al.   MOLECULAR CANCER THERAPEUTICS

PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy

(2010) Jitesh P. Jani et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor

(2010) Sushant K. Kachhap et al.   PLoS One

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

(2010) Stephanie Jeske et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The substrates of Plk1, beyond the functions in mitosis

(2010) X. Shawn Liu et al.   Protein & Cell

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1

(2009) Kelly Anderson et al.   BIOCHEMICAL JOURNAL

Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

(2009) A. G. Gilmartin et al.   CANCER RESEARCH

K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells

(2009) R. Nakai et al.   CANCER RESEARCH

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

(2009) Puneet Chopra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting

(2009) S. Sewak et al.   INTERNAL MEDICINE JOURNAL

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

(2009) Adam D. Judge et al.   JOURNAL OF CLINICAL INVESTIGATION

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium

(2009) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

(2009) Neeltje Steeghs et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

(2009) D.R. Shepard et al.   JOURNAL OF UROLOGY

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

(2009) E. C. VanderPorten et al.   MOLECULAR CANCER THERAPEUTICS

Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer

(2009) A. Sella et al.   ONCOLOGY

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

(2008) A. Hussain et al.   ANNALS OF ONCOLOGY

Mechanism of Inhibition of Human KSP byIspinesib

(2008) Latesh Lad et al.   BIOCHEMISTRY

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

(2008) S P Blagden et al.   BRITISH JOURNAL OF CANCER

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer

(2008) William Kevin Kelly et al.   CANCER

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

(2008) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications

(2008) V. Sarli et al.   CLINICAL CANCER RESEARCH

Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

(2008) Tomasz M. Beer et al.   Clinical Genitourinary Cancer

Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development

(2008) Tohru Takaki et al.   CURRENT OPINION IN CELL BIOLOGY

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

(2008) I. Tamaskar et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer

(2008) Nicholas J. Sanfilippo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY